The 1st Psoriasis Symposium, organised by the Psoriasis Association of Bosnia and Herzegovina in collaboration with the Skin Inflammation & Psoriasis International Network (SPIN), the International Society of Dermatology and the European Academy of Dermatology and Venerology, was held in Sarajevo on 13-15 October 2017.
The Symposium was intended to provide delegates with the latest research and facts on diagnoses and genetics of psoriasis and psoriatic arthritis, long-term treatment with available therapies and treatments in development.
Approximately 200 participants and 40 guests from 22 countries across three continents participated in the Symposium.
The Symposium’s scientific programme included lectures by 26 international invited speakers, with the aim of presenting contemporary achievements in psoriasis and exchanging experiences.
There were 46 lectures and 21 poster presentations as well as 5 sponsored satellite symposia.
The main topics of the Symposium were:
- Immune system and psoriatic disease
- Psoriasis as a systemic disease
- Psoriasis in childhood and pregnancy
- Clinical and diagnostic characteristics of psoriasis and psoriatic arthritis
- Psoriasis therapy: from conventional therapies to biological drugs
- Free themes
As a partner organization, SPIN organized a session during this meeting.
Following the welcome and introductory speeches of SPIN Chair Professor Jo Lambert, lectures were held by the members of the SPIN Scientific Committee:
- Prof. Nejib Doss, Tunisia: Nail psoriasis: differential diagnosis
- Prof. Christopher Griffiths, UK: Systems medicine and psoriasis management
- Prof. Romana Ceovoc, Croatia: Topical treatments and phototherapy in the era of biologics
- Prof. Thomas A. Luger, Germany: Novel therapies for psoriasis: where are we going?
- Prof. Jo Lambert, Belgium: Tailored prescribing of biologicals: a challenge for the near future.
That event was also marked by the celebration of World Psoriasis Day - a day for awareness and advocacy for all people living with psoriasis and psoriatic arthritis around the world!
Rich cultural and social programs and the unique multicultural spirit and historical heritage of Sarajevo city have contributed to the good mood of all participants wishing to meet again and to exchange some new experiences.
SPIN Presentation
Recent news
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
- 2018/07/16 Focus on...
- 2018/07/09 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
IL-33 contributes to disease severity in Psoriasis-like models of mouse.
Duan Y et al.
IL-33 contributes to disease severity in Psoriasis-like models of mouse.
Cytokine.
2019 Jul , 119:159-167.
Immune cells infiltrating the psoriatic skin secrete high amounts of pro-inflammatory cytokines IL-17, TNF-α, IL-21 and IL-36 resulting in chronic inflammation. However, the exact cellular and molecular mechanisms have not been fully understood. We report here elevation of IL-33 expression in psoriatic lesions. Studies in imiquimod (IMQ)-induced mice with psoriatic inflammation confirmed a critical role for IL-33 in driving the disease. IL-33 reduces the CD4 and CD8 cells, inhibits autophagy (...)
see on pubmed
Association of plasma and urine metals levels with kidney function: A population-based cross-sectional study in China.
Chemosphere.
2019 Jul , 226:321-328.
Although environmental exposure to multiple metals is common, epidemiological studies on the associations of exposure to 23 metals with kidney function have not been analyzed. We aimed to investigate the associations of 23 metals levels with renal function.
see on pubmed
Models of human psoriasis: Zebrafish the newly appointed player.
Martínez-Navarro FJ et al.
Models of human psoriasis: Zebrafish the newly appointed player.
Dev. Comp. Immunol..
2019 Aug , 97:76-87.
Psoriasis is a human chronic, immune disease with severe cutaneous and systemic manifestations. Its prevalence, among the world population, highly varies with ethnicity and geography, but not sex from remarkable low levels in Asia to 2.3% in Spain, or an impressive 11.5% in Norway. The pathogenesis of psoriasis derives from complex genetic and environmental interactions, which creates aberrant crosstalk between keratinocytes and variated immune cell, resulting in open amplified inflammatory (...)
see on pubmed
on Atopic Dermatitis
What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment.
Clin. Exp. Dermatol..
2019 Jun , 44, (4):376-380.
This review forms part of a series of annual updates that summarize the evidence base for atopic eczema (AE). It presents the key findings from 11 systematic reviews published in 2016 that focus on AE outcome assessment, disease impact and nomenclature. Systematic reviews on the treatment and prevention of AE are summarized in Part 1 of this update, and systematic reviews on the epidemiology of and risk factors for AE are summarized in Part 2. Six reviews summarized what outcome measurement (...)
see on pubmed
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.
Bioorg. Med. Chem. Lett..
2019 Jun 15, 29, (12):1522-1531.
Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
